Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

NCT06180382 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Adalimumab
DRUG: Vedolizumab

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Collaborators

[object Object]